IBA to develop, distribute PSMA PET/CT agent for ImaginAb

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

ImaginAb announced earlier this month that IBA Molecular will be taking on radiochemistry, manufacturing and distribution of the diagnostic immunoPET agent for prostate cancer, Zr-89 Df-IAB2M, as U.S. clinical trials roll out.

The development and distribution of Zr-89 Df-IAB2M will be happening out of IBA’s Richmond, Va., and Somerset, N.J., radiopharmaceutical facilities.

"This product has the potential to impact patient care by correctly assessing the extent of disease in several high-risk patient populations so that better clinical decisions can be made," said Christian P. Behrenbruch, MBA, PhD, CEO of ImaginAb, in a press release. "We are pleased to select IBA Molecular to provide centralized radiopharmaceutical manufacturing and supply of 89Zr-Df-IAB2M to our clinical trial sites. Their experience with biologics and longer half-life isotopes like Zr-89 and I-124 was central to our decision."

Zr-89 Df-IAB2M is ImaginAb’s banner PET/CT radiotracer candidate and is comprised of a radio-cc antibody fragment—what the company calls a "Minibody." This drug candidate is currently being evaluated for the detection of metastatic prostate cancer in soft tissue and bone. The IAB2M monoclonal antibody fragment seeks out prostate-specific membrane antigen (PSMA), which the company says could be ideal as a biomarker for androgen depletion.

"We are pleased to have been selected by ImaginAb to conduct the radiopharmaceutical manufacturing for this promising imaging agent," said Lee Karras, president of IBA Molecular North America in the release. "IBA Molecular is well positioned for the supply of this clinical tracer through the combination of large-scale Zr-89 isotope production at our Richmond, Va. site and [good current manufacturing practices] and radiolabeling from our Somerset, N.J. facility. Our innovative development and manufacturing platforms are helping bring new and potentially impactful diagnostic and therapeutic products to the market, with the ultimate goal of improving patient care."

 

Kathy Mahdoubi

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.